Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection Journal Article
| Authors: | Downey, R. J.; Akhurst, T.; Gonen, M.; Vincent, A.; Bains, M. S.; Larson, S.; Rusch, V. |
| Article Title: | Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection |
| Abstract: | Purpose: A retrospective review of surgically treated lung cancer patients imaged preoperatively by F-18 fluorodeoxyglucose-positron emission tomography ([18F]FDG-PET) to determine if the primary tumor standardized uptake value (SUV) predicts survival. Patients and Methods: Non-small-cell lung cancer or carcinoid pT1-4, N0-2, M0 patients treated by R0 surgical resection alone were imaged with computed tomography scan and PET within 90 days before surgery. Prognostic variables were assessed by log-rank test; survival was assessed by the method of Kaplan and Meier. Results: One hundred consecutive patients (48 men, 52 women) were retrospectively reviewed. Median follow-up for surviving patients was 28 months (range, 16 to 81 months). Median maximal SUV (SUV MAX) was 9. The 2-year survival for patients with SUVMAX more than 9 was 68% and for those with SUVMAX less than 9, it was 96% (P < .01, log-rank test). In a multivariate analysis including pathologic tumor size, involved nodes, histology, and SUVMAX, only tumor size (T) more than 3 cm and SUVMAX more than 9 and their interaction were significant predictors of survival (P = .01, 0.02, and < 0.01, respectively). The 3-year survivals for patients with both T less than 3 cm and SUV MAX less than 9 was 97%; for those with T less than 3 cm and SUV MAX more than 9, it was 94%; for those with T more than 3 cm and SUVMAX less than 9, it was 93%; and for those with T more than 3 cm and SUVMAX more than 9, it was 47% (P < .01). Conclusion: In surgically managed lung cancer patients, SUV is a predictor of overall survival after resection. The addition of SUVMAX to pathologic tumor size identifies a subgroup of patients at highest risk for death as a result of recurrent disease after resection. © 2004 by American Society of Clinical Oncology. |
| Keywords: | survival; adult; cancer survival; aged; middle aged; survival analysis; cancer surgery; retrospective studies; major clinical study; review; preoperative care; positron emission tomography; follow up; sensitivity and specificity; radiopharmaceuticals; tumor volume; lung non small cell cancer; carcinoma, non-small-cell lung; lung neoplasms; pathology; retrospective study; prediction; lung tumor; diagnostic agent; fluorodeoxyglucose f 18; computer assisted emission tomography; fluorodeoxyglucose f18; prediction and forecasting; predictive value of tests; radiopharmaceutical agent; scintiscanning; carcinoid; multivariate analysis; carcinoid tumor; tomography, emission-computed; humans; prognosis; human; male; female; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 22 |
| Issue: | 16 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2004-08-15 |
| Start Page: | 3255 |
| End Page: | 3260 |
| Language: | English |
| DOI: | 10.1200/jco.2004.11.109 |
| PROVIDER: | scopus |
| PUBMED: | 15310769 |
| DOI/URL: | |
| Notes: | J. Clin. Oncol. -- Cited By (since 1996):223 -- Export Date: 16 June 2014 -- CODEN: JCOND -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work